Valproic acid and central sleep apnea: a retrospective analysis

Affiliations

¹ Division of Sleep Medicine, Mayo Clinic, Scottsdale, Arizona, USA. martin.kari@mayo.edu.
² Division of Pulmonary Medicine, Mayo Clinic, Scottsdale, Arizona, USA.
³ Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA.
⁴ Division of Sleep Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Kari A Martin et al. Sleep Breath. 2025.

. 2025 Apr 26;29(2):171.

doi: 10.1007/s11325-025-03334-y.

¹ Division of Sleep Medicine, Mayo Clinic, Scottsdale, Arizona, USA. martin.kari@mayo.edu.
² Division of Pulmonary Medicine, Mayo Clinic, Scottsdale, Arizona, USA.
³ Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA.
⁴ Division of Sleep Neurology, Mayo Clinic, Rochester, Minnesota, USA.

No abstract available

Keywords: Central sleep apnea; Depakote; Drug-induced sleep apnea; Valproic acid.

Conflict of interest statement

Declarations. Conflict of interest: None. Financial support: No declarations. All authors have seen and approved the manuscript.

1. Guichard K, Micoulaud-Franchi J-A, Coulon P, Ghorayeb I, Philip P (2019) 1032 Reversible central sleep apnea syndrome induced by valproic acid treatment: a case report. Sleep 42(Supplement1):A414–A15 - DOI
1. Guichard K, Micoulaud-Franchi JA, McGonigal A et al (2019) Association of valproic acid with central sleep apnea syndrome: two case reports. J Clin Psychopharmacol 39(6):681–684 - DOI - PubMed
1. Baillieul S, Pepin JL, Tamisier R, Verbraecken J (2024) Medication-induced central sleep apnea: beyond the unification of concepts, seizing the opportunity to precision medicine. Sleep.;47(8)